Jeffrey S. Ross

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer

  Clinical Cancer Research · 2025-12-04 · 1 citations

• Supplementary Table S5 from Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial

  2025-11-25

• Supplementary Figure S5 from Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple <i>PIK3CA</i> Mutations

  2025-11-25

• Supplementary Figure S7 from Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple <i>PIK3CA</i> Mutations

  2025-11-25

• Supplementary Figure S3 from Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple <i>PIK3CA</i> Mutations

  2025-11-25

• Supplementary Figures S1-S4 from Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial

  2025-11-25

• Supplementary Table S2 from Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial

  2025-11-25

• Supplementary Table S3 from Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial

  2025-11-25

• Supplementary Table S1 from Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial

  2025-11-25

• Supplementary Figure S6 from Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple <i>PIK3CA</i> Mutations

  2025-11-25

• Supplementary Figure S2 from Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple <i>PIK3CA</i> Mutations

  2025-11-25

• Supplementary Figure S1 from Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple <i>PIK3CA</i> Mutations

  2025-11-25

• Supplementary Figure S8 from Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple <i>PIK3CA</i> Mutations

  2025-11-25

• Supplementary Tables S1-14 from Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple <i>PIK3CA</i> Mutations

  2025-11-25

• Supplementary Figure S4 from Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple <i>PIK3CA</i> Mutations

  2025-11-25

• Supplementary Table S4 from Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial

  2025-11-25

• DNMT3A and NPM1 co-mutations in Acute Myeloid Leukemia (AML): A genomic landscape study

  Blood · 2025-11-03

• NUP98 rearrangements (NUP98r) in Acute Myeloid Leukemia (AML): A genomic landscape study

  Blood · 2025-11-03

• Prostate Cancer Grading

  Urologic Clinics of North America · 2025-10-23

• 2697P Comprehensive genomic profiling in chordoma by subtype classification

  Annals of Oncology · 2025-09-01